These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 28056755)

  • 1. Common Therapeutic Modalities Against Diabetes and Associated Cardiovascular Disease.
    Jabir NR; Firoz CK; Ashraf GM; Zaidi SK; Shakil S; Kamal MA; Tabrez S
    Curr Vasc Pharmacol; 2017; 15(4):365-373. PubMed ID: 28056755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kalpaamruthaa modulates oxidative stress in cardiovascular complication associated with type 2 diabetes mellitus through PKC-β/Akt signaling.
    Latha R; Shanthi P; Sachdanandam P
    Can J Physiol Pharmacol; 2013 Nov; 91(11):901-12. PubMed ID: 24117257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac oxidative stress in diabetes: Mechanisms and therapeutic potential.
    Faria A; Persaud SJ
    Pharmacol Ther; 2017 Apr; 172():50-62. PubMed ID: 27916650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT1 inhibition boon or bane for diabetes-associated cardiomyopathy.
    Kalra J; Mangali SB; Dasari D; Bhat A; Goyal S; Dhar I; Sriram D; Dhar A
    Fundam Clin Pharmacol; 2020 Apr; 34(2):173-188. PubMed ID: 31698522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of the importance of glycaemic control for cardiovascular events in the in-and out-patient setting.
    Anselmino M; Malmberg K; Mellbin L; Rydén L
    Rev Endocr Metab Disord; 2010 Mar; 11(1):87-94. PubMed ID: 20204530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inflammatory property of Kalpaamruthaa on myocardium in type 2 diabetes mellitus induced cardiovascular complication.
    Raja L; Palanivelu S; Panchanatham S
    Immunopharmacol Immunotoxicol; 2013 Feb; 35(1):119-25. PubMed ID: 22870884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myocardial metabolism in diabetic cardiomyopathy: potential therapeutic targets.
    Sung MM; Hamza SM; Dyck JR
    Antioxid Redox Signal; 2015 Jun; 22(17):1606-30. PubMed ID: 25808033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuation of Diabetes-induced Cardiac and Subcellular Defects by Sulphur-containing Amino Acids.
    Tappia PS; Adameova A; Dhalla NS
    Curr Med Chem; 2018 Jan; 25(3):336-345. PubMed ID: 28685680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes mellitus and oral care.
    Fiske J
    Dent Update; 2004 May; 31(4):190-6, 198. PubMed ID: 15188524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacterial resistance and failure of clinical cure could be produced by oxidative stress in patients with diabetes or cardiovascular diseases during fluoroquinolone therapy.
    Aragon-Martinez OH; Martinez-Morales F; Isiordia-Espinoza MA; Luque Contreras D; Zapata Morales JR; Gonzalez-Rivera ML
    Med Hypotheses; 2017 Jun; 103():32-34. PubMed ID: 28571804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coming full circle in diabetes mellitus: from complications to initiation.
    Harcourt BE; Penfold SA; Forbes JM
    Nat Rev Endocrinol; 2013 Feb; 9(2):113-23. PubMed ID: 23296171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lipids--Diagnosis and therapy in diabetes mellitus].
    Wascher TC; Paulweber B; Toplak H; Säly CH; Drexel H; Föger B; Hoppichler F
    Wien Klin Wochenschr; 2016 Apr; 128 Suppl 2():S68-70. PubMed ID: 27052223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between glycaemic variability and cardiovascular complications in patients with acute myocardial infarction and type 2 diabetes: a report from the DIGAMI 2 trial.
    Mellbin LG; Malmberg K; Rydén L; Wedel H; Vestberg D; Lind M
    Eur Heart J; 2013 Feb; 34(5):374-9. PubMed ID: 23144046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental evidence for curcumin and its analogs for management of diabetes mellitus and its associated complications.
    Rivera-Mancía S; Lozada-García MC; Pedraza-Chaverri J
    Eur J Pharmacol; 2015 Jun; 756():30-7. PubMed ID: 25769841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology of cardiovascular complications in type 2 diabetes mellitus.
    Meigs JB
    Acta Diabetol; 2003 Dec; 40 Suppl 2():S358-61. PubMed ID: 14704869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of insulin to improve glycemic control in diabetes mellitus.
    Dandona P; Chaudhuri A; Ghanim H; Mohanty P
    Cardiovasc Drugs Ther; 2008 Jun; 22(3):241-51. PubMed ID: 18347965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes mellitus--overview.
    Hoogwerf BJ; Sferra J; Donley BG
    Foot Ankle Clin; 2006 Dec; 11(4):703-15. PubMed ID: 17097511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidative stress and antioxidant treatment in diabetes.
    Scott JA; King GL
    Ann N Y Acad Sci; 2004 Dec; 1031():204-13. PubMed ID: 15753146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antioxidant edaravone prevents cardiac dysfunction by suppressing oxidative stress in type 1 diabetic rats and in high-glucose-induced injured H9c2 cardiomyoblasts.
    Ji L; Liu Y; Zhang Y; Chang W; Gong J; Wei S; Li X; Qin L
    Can J Physiol Pharmacol; 2016 Sep; 94(9):996-1006. PubMed ID: 27376621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promising new approaches.
    Reasner CA
    Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.